Dipeptidyl peptidase 4(DPP-4)is a clinically validated target for the treatment of type 2 diabetes mellitus(T2DM).To discover novel and potent DPP-4 inhibitors,
Nanozymes with intrinsic enzyme-like properties have attracted significant interest owing to their capability to address the limitations of traditional enzymes